Manufacturer with High Purity and Stable Quality
Chemical Name: Ropivacaine Hydrochloride Monohydrate
Synonyms: Ropivacaine HCl.H2O
CAS: 132112-35-7
An anaesthetic agent and blocks impulse conduction in nerve fibres through inhibiting sodium ion influx reversibly
API USP Standard, High Quality, Commercial Production
| Chemical Name |
Ropivacaine Hydrochloride Monohydrate |
| Synonyms |
Ropivacaine HCl.H2O |
| CAS Number |
132112-35-7 |
| CAT Number |
RF-API42 |
| Stock Status |
In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula |
C17H26N2O.ClH.H2O |
| Molecular Weight |
328.88 |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White Powder |
| Identification |
(1) It should be positive reaction
(2) IR: Meets the requirement |
| Color |
The absorbance at 405nm is not more than 0.030
The absorbance at 436nm is not more than 0.025 |
| pH |
4.5~6.0 |
| Related Substances |
|
| Total Impurity |
≤0.50% |
| Single Impurity |
≤0.10% |
| Bupivacaine |
≤0.20% |
| Optical Isomers |
≤0.50% |
| Water |
5.0%~6.0% |
| Heavy Metals |
≤10ppm |
| 2,6-Dimethylaniline |
≤10ppm |
| Specific Rotation |
Obtain readings at 365 nm: between -210° ~ -255° |
| Assay |
98.5%~101.0% |
| Test Standard |
United States Pharmacopeia (USP) Standard |
| Usage |
Active Pharmaceutical Ingredient (API) |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of Ropivacaine Hydrochloride Monohydrate (CAS: 132112-35-7) with high quality.
Ropivacaine hydrochloride monohydrate is an anaesthetic agent and blocks impulse conduction in nerve fibres through inhibiting sodium ion influx reversibly. Ropivacaine is a long-acting amide local anaesthetic agent and first produced as a pure enantiomer. It produces effects similar to other local anaesthetics via reversible inhibition of sodium ion influx in nerve fibres. Ropivacaine is less lipophilic than bupivacaine and is less likely to penetrate large myelinated motor fibres, resulting in a relatively reduced motor blockade. Thus, ropivacaine has a greater degree of motor sensory differentiation, which could be useful when motor blockade is undesirable. The reduced lipophilicity is also associated with decreased potential for central nervous system toxicity and cardiotoxicity. The drug displays linear and dose proportional pharmacokinetics (up to 80 mg administered intravenously). It is metabolised extensively in the liver and excreted in urine. The present article details the clinical applications of ropivacaine and its current place as a local anaesthetic in the group.